Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugs

American Journal of Medicine

Volumn 110, Issue 3 SUPPL. 1, 2001, Pages 20-27

  Hernández Díaz, Sonia ^a   García Rodríguez, Luis Alberto ^b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b Harvard School of Public Health ^*  (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; AZAPROPAZONE; DICLOFENAC; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; STEROID; SULINDAC;

ADULT; AGE; AGED; DATA BASE; DIGESTIVE SYSTEM PERFORATION; DOSE RESPONSE; DRUG EFFECT; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART FAILURE; HUMAN; INCIDENCE; KIDNEY INJURY; LIVER INJURY; MALE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; UNITED KINGDOM;

EID: 0035911003     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(00)00682-3     Document Type: Review

References (56)

1. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: Population based case-control study
2. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons
3. Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs
4. Risks of bleeding peptic ulcer associated with individual nonsteroidal anti-inflammatory drugs
5. Risk of upper gastrointestinal bleeding and perforation associated with individual nonsteroidal anti-inflammatory drugs
6. Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation
7. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs
8. Upper gastrointestinal bleeding in relation to previous use of analgesics and nonsteroidal antiinflammatory drugs
9. Nonsteroidal anti-inflammatory drugs and upper gastrointestinal bleeding, a post-marketing surveillance case-control study
10. Nonsteroidal antiinflammatory drugs and gastrointestinal hospitalizations in Saskatchewan: A cohort study
11. Nonsteroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding
12. Variation in the risk of peptic ulcer complications with nonsteroidal antiinflammatory drug therapy
13. Peptic ulcer and gastrointestinal hemorrhage associated with nonsteroidal anti-inflammatory drug use in patients younger than 65 years. A large health maintenance organization cohort study
14. Nonsteroidal anti-inflammatory drugs and hospital admission for perforated peptic ulcer
15. The association of nonsteroidal anti-inflammatory drugs with upper gastrointestinal tract bleeding
16. A cohort study (with re-sampled comparator groups) to measure the association between new NSAID prescribing and upper gastrointestinal hemorrhage and perforation
17. The impact of research quality and study design on epidemiologic estimates of the effect of nonsteroidal anti-inflammatory drugs on upper gastrointestinal tract disease
18. Variability in risk of gastrointestinal complications with individual nonsteroidal anti-inflammatory drugs: Results of a collaborative meta-analysis
19. Nonsteroidal antiinflammatory drugs, ulcers and risk: A collaborative meta-analysis
20. Gastroduodenal toxicity of different nonsteroidal antiinflammatory drugs
21. Alcohol consumption and the risk of upper gastrointestinal bleeding
22. Liver disease associated with diclofenac, naproxen and piroxicam
23. The role of nonsteroidal anti-inflammatory drugs in acute liver injury
24. Safety of nonsteroidal anti-inflammatory drugs with respect to acute liver disease
25. Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors
26. Incidence of symptomatic liver function abnormalities in a cohort of NSAIDs users
27. Quantitative studies of the risk of serious hepatic injury in persons using nonsteroidal antiinflammatory drugs
28. The increased risk of hospitalizations for acute liver injury in a population with exposure to multiple drugs
29. Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease
30. End-stage renal disease and non-narcotic analgesic: A case-control study
31. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs
32. Nonsteroidal anti-inflammatory drugs and the risk of hospitalization for acute renal failure
33. Nonsteroidal anti-inflammatory drugs and acute renal disease: A case-control study
34. Nonsteroidal anti-inflammatory drugs and hospitalization for acute renal failure
35. Consumption of nonsteroidal anti-inflammatory drugs and the development of functional renal impairment in elderly subjects. Results of a case-control study
36. Renal effects of ibuprofen, piroxicam, and sulindac in patients with asymptomatic renal failure
37. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics
38. Consumption of NSAIDs and development of congestive heart failure in elderly patients: An underrecognized public health problem
39. A prospective study of drugs and pregnancy
40. First-trimester drug use and congenital disorders
41. The relation of aspirin use during the first trimester of pregnancy to congenital cardiac defects
42. Maternal medications and environmental exposures as risk factors for gastroschisis
43. First trimester maternal medication use in relation to gastroschisis
44. Exogenous hormones and other drug exposures of children with congenital heart disease
45. Associations between drugs administered during pregnancy and congenital abnormalities of the fetus
46. Prescription drug use before and during pregnancy in a Medicaid population
47. Antirheumatic medication in pregnancy
48. NSAIDs: Maternal and fetal considerations
49. Nonsteroidal anti-inflammatory drugs during pregnancy
50. The risk and benefits of taking aspirin during pregnancy
51. Differences in NSAID tolerability profiles. Fact or fiction?
52. Oligohydramnios associated with prostaglandin synthetase inhibitors in preterm labor
53. Antenatal indomethacin - Adverse fetal effects confirmed
54. An assessment of the safety of pediatric ibuprofen: A practitioner-based randomized clinical trial